Artemether-lumefantrine versus artemisinin-naphthoquine in Papua New Guinean children with uncomplicated malaria: a six months post-treatment follow-up study

[1]  P. Siba,et al.  Artemether-lumefantrine versus artemisinin-naphthoquine in Papua New Guinean children with uncomplicated malaria: a six months post-treatment follow-up study , 2015, Malaria Journal.

[2]  G. Shanks,et al.  Evolution from double to triple-antimalarial drug combinations. , 2015, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[3]  Stephan Karl,et al.  Artemisinin-Naphthoquine versus Artemether-Lumefantrine for Uncomplicated Malaria in Papua New Guinean Children: An Open-Label Randomized Trial , 2014, PLoS medicine.

[4]  B. J. Visser,et al.  Efficacy and safety of artemisinin combination therapy (ACT) for non-falciparum malaria: a systematic review , 2014, Malaria Journal.

[5]  B. V. D. van den Borne,et al.  Factors related to retention of community health workers in a trial on community-based management of fever in children under 5 years in the Dangme West District of Ghana. , 2014, International health.

[6]  P. Siba,et al.  Comparison of an assumed versus measured leucocyte count in parasite density calculations in Papua New Guinean children with uncomplicated malaria , 2014, Malaria Journal.

[7]  J. Crump,et al.  Evaluation of In-Hospital Management for Febrile Illness in Northern Tanzania before and after 2010 World Health Organization Guidelines for the Treatment of Malaria , 2014, PloS one.

[8]  A. Rosanas-Urgell,et al.  Severe Anemia in Papua New Guinean Children from a Malaria-Endemic Area: A Case-Control Etiologic Study , 2012, PLoS neglected tropical diseases.

[9]  P. Siba,et al.  Artemisinin-Naphthoquine Combination Therapy for Uncomplicated Pediatric Malaria: a Pharmacokinetic Study , 2012, Antimicrobial Agents and Chemotherapy.

[10]  P. Siba,et al.  Characterization of Treatment Failure in Efficacy Trials of Drugs against Plasmodium vivax by Genotyping Neutral and Drug Resistance-Associated Markers , 2011, Antimicrobial Agents and Chemotherapy.

[11]  P. Siba,et al.  Desbutyl-Lumefantrine Is a Metabolite of Lumefantrine with Potent In Vitro Antimalarial Activity That May Influence Artemether-Lumefantrine Treatment Outcome , 2011, Antimicrobial Agents and Chemotherapy.

[12]  P. Rosenthal,et al.  Artemether-lumefantrine versus dihydroartemisinin-piperaquine for falciparum malaria: a longitudinal, randomized trial in young Ugandan children. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[13]  P. Rosenthal,et al.  Artemether-Lumefantrine versus Dihydroartemisinin-Piperaquine for Treating Uncomplicated Malaria: A Randomized Trial to Guide Policy in Uganda , 2008, PloS one.

[14]  K. Stȩpniewska,et al.  Pharmacokinetic Determinants of the Window of Selection for Antimalarial Drug Resistance , 2008, Antimicrobial Agents and Chemotherapy.

[15]  I. Mueller,et al.  The risk of malarial infections and disease in Papua New Guinean children. , 2007, The American journal of tropical medicine and hygiene.

[16]  Umberto D'Alessandro,et al.  Variation in malaria transmission intensity in seven sites throughout Uganda. , 2006, The American journal of tropical medicine and hygiene.

[17]  W. Watkins,et al.  The search for effective and sustainable treatments for Plasmodium falciparum malaria in Africa: a model of the selection of resistance by antifolate drugs and their combinations. , 2005, The American journal of tropical medicine and hygiene.

[18]  R. Price,et al.  In Vivo Assessment of Drug Efficacy against Plasmodium falciparum Malaria: Duration of Follow-Up , 2004, Antimicrobial Agents and Chemotherapy.

[19]  A. Hubbard,et al.  Distinguishing recrudescence from reinfection in a longitudinal antimalarial drug efficacy study: comparison of results based on genotyping of msp-1, msp-2, and glurp. , 2003, The American journal of tropical medicine and hygiene.

[20]  M. Molyneux,et al.  Nontyphoidal Salmonella infections of children in tropical Africa , 2000, The Pediatric infectious disease journal.

[21]  M. Molyneux,et al.  Bacteremia in febrile Malawian children: clinical and microbiologic features , 2000, The Pediatric infectious disease journal.

[22]  N. White,et al.  Antimalarial drug resistance and combination chemotherapy. , 1999, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.

[23]  J. Karbwang,et al.  Population pharmacokinetics and therapeutic response of CGP 56697 (artemether + benflumetol) in malaria patients. , 1998, British journal of clinical pharmacology.

[24]  S. Nagase,et al.  [PCR-RFLP analysis]. , 1996, Tanpakushitsu kakusan koso. Protein, nucleic acid, enzyme.

[25]  M. Alpers,et al.  Resistance of Plasmodium falciparum malaria to amodiaquine, chloroquine and quinine in the Madang Province of Papua New Guinea, 1990-1993. , 1996, Papua and New Guinea medical journal.

[26]  R. Snow,et al.  Assessment and monitoring of antimalarial drug efficacy for the treatment of uncomplicated falciparum malaria , 2003 .

[27]  I. Felger,et al.  Genotyping of Plasmodium falciparum. PCR-RFLP analysis. , 2002, Methods in molecular medicine.

[28]  I. Felger,et al.  Genotyping of Plasmodium falciparum , 2002 .

[29]  M. Alpers,et al.  The epidemiology of malaria in a population surrounding Madang, Papua New Guinea. , 1986, The American journal of tropical medicine and hygiene.